Maxacalcitol Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a secosteroidal vitamin D receptor agonist supplied as the 22-oxa analogue of calcitriol. The material is released for incorporation into low-dose solid oral dosage forms and injectable finished drug product where the active pharmaceutical ingredient is present in the microgram range. Two physical grades are commonly used: a micronized grade for direct compression or capsule filling and a crystalline grade for wet or dry granulation. The certificate of analysis should state particle size distribution by laser diffraction according to ISO 13320, loss on drying, residue on ignition, residual solvent profile, and assay relative to a pharmacopoeial reference standard. For injectable applications, additional release controls for bacterial endotoxins, bioburden, and subvisible particulate matter after reconstitution are required. The product is not interchangeable with calcitriol, alfacalcidol, doxercalciferol, or paricalcitol without formulation revalidation: the 22-oxa side-chain changes lipophilicity, oxidative sensitivity, and vitamin D receptor transactivation behavior compared with the parent secosteroid. In finished product, Maxacalcitol is used for suppression of parathyroid hormone secretion in secondary hyperparathyroidism associated with end-stage renal disease. Because the therapeutic dose is low, the API imposes stricter uniformity, cleaning, and cross-contamination controls than high-dose drugs.

What release specifications and ICH compliance thresholds govern the API for dual oral and parenteral routes?

Release specifications are route-dependent. For oral solid dosage forms, the API release panel typically includes appearance, identification by infrared absorption and high-performance liquid chromatography retention time, assay, related substances, residual solvents, elemental impurities, water content, and particle size distribution. A pharmacopoeial assay window of 98.0%–102.0% on the anhydrous basis is common; a tighter registered specification may be justified by stability data. Related substances are controlled under ICH Q3A. For a maximum daily dose of 10 mg or less, the identification threshold is 0.10% or 1.0 mg total daily intake, whichever is lower, and the qualification threshold is 0.15% or 1.0 mg total daily intake, whichever is lower. Because Maxacalcitol doses are in the microgram range, the percentage thresholds remain the critical limits; the absolute daily intake mass may be many orders of magnitude higher than the actual impurity burden. Residual solvents are controlled by ICH Q3C Option 1 for Class 1, Class 2, and Class 3 solvents. Injectable grades require a headspace gas chromatography method with sufficient sensitivity to detect Class 1 solvents below their limiting concentrations. Elemental impurities are assessed per ICH Q3D for both oral and parenteral permitted daily exposure values; the parenteral assessment applies the more restrictive limits for cadmium, lead, arsenic, mercury, and catalyst-derived elements. Because the secosteroid is sensitive to oxygen and light, the container closure system commonly uses amber glass or foil laminate with desiccant and oxygen absorber under nitrogen headspace. Stability-indicating methods are validated according to ICH Q2(R1). Long-term storage is typically controlled at 2–8°C, with accelerated testing at 25°C/60% RH and photostability testing under ICH Q1B.

Because the therapeutic dose is in the microgram range, direct compression and capsule filling are constrained by segregation, electrostatic adhesion, and dissolution of the micronized API. A drug load below 0.1% w/w is not blended directly. A pre-blend at 1:10 API-to-diluent ratio is prepared in a V-blender or bin blender fitted with an intensifier bar, then diluted geometrically to an intermediate concentration near 0.5% w/w before final lubrication. Magnesium stearate is added at the end, with total lubrication time limited to 3–5 min to avoid overlubrication and dissolution slowdown. Dissolution is monitored by USP <711> Apparatus 2 or JP 18 General Test 6.10, with the method selected to maintain sink conditions. Granulation may be required when direct compression produces an acceptance value greater than 15 under USP <905> or JP 18 General Test 6.02. For low-dose granulation, Maxacalcitol can be dissolved in ethanol and sprayed onto mannitol or microcrystalline cellulose in a fluid-bed granulator with a Wurster column. The spray rate and inlet air dew point are controlled to limit thermal degradation and moisture uptake. Because the molecule is oxygen-sensitive, the granulation headspace is nitrogen-blanketed and the product temperature is maintained below 35°C. Production-scale bottlenecks include electrostatic charging of micronized API during transfer, wall losses, and blend assay drift. Contact surfaces should be 316L stainless steel or compatible polymer, with grounding and relative humidity maintained at or below 40% RH in weighing and sifting suites. Cross-contamination control for a microgram-level API requires dedicated suites, validated cleaning limits, and swab sampling analyzed by LC-MS/MS. Batch-to-batch variance in particle size at D90 above 15 µm may cause content uniformity failure in direct compression. Micronized API is therefore typically controlled with D90 not greater than 10 µm and D50 in the 2–5 µm range, measured by laser diffraction with dry dispersion at 0.1–0.3 MPa air pressure according to ISO 13320.

Particle geometry, specific surface area, and photodegradation limits in injectable formulation

Because Maxacalcitol is a hydrophobic secosteroid, aqueous injectable formulation requires a cosolvent system, a surfactant-based micellar vehicle, or a cyclodextrin inclusion complex. The choice changes the ability to use terminal sterilization. Terminal moist heat sterilization at 121°C for 15 min is generally incompatible with the 22-oxa side-chain when oxygen and trace iron are present. Oxidative degradation produces compounds with altered vitamin D receptor binding. Production-scale injectable processing therefore commonly uses aseptic filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane. The API is pre-dissolved in a sterile-filtered ethanol/propylene glycol phase under nitrogen. Filter compatibility is evaluated for plastic components according to ISO 10993 or USP <88>, and maximum filtration pressure is controlled to prevent particle shedding. Bacterial retention of the filter is verified with Brevundimonas diminuta at a challenge of 10⁷ CFU per cm² according to ASTM F838-20. Endotoxin control for the parenteral finished product is tested by USP <85> or JP 18 Bacterial Endotoxins Test. The limit is derived from the maximum adult dose using the K/M formula, commonly yielding a limit in the range of 0.5–5.0 EU per mg of API or per vial, subject to route and dosing schedule. The API for injectable use must also meet clarity and particulate controls after reconstitution. Visible particles are assessed per USP <790>, and subvisible particles per USP <788> or Ph. Eur. 2.9.19. Processing under yellow or red light is required because the vitamin D triene chromophore undergoes photoisomerization. Light protection is validated under ICH Q1B. Storage with nitrogen headspace reduces pre-vial precipitation and oxidative damage.

When Maxacalcitol injection routes are terminal sterilized rather than aseptically filtered, which stability-limiting degradation pathways appear first?

When Maxacalcitol injection routes are terminal sterilized rather than aseptically filtered, the stability-limiting pathways that appear first are oxidative opening of the secosteroid ring and cis-trans isomerism of the triene chromophore. Forced degradation at 80°C in the presence of hydrogen peroxide or transition-metal spiking can generate degradation products detectable by HPLC, but published data for this specific configuration is limited. The formulation cannot be autoclaved without an oxygen-scavenging overlay and metal chelator; even then, assay loss may exceed 5% after 15 min at 121°C. Aseptic filtration is therefore preferred when short heat exposure and a release assay of 98.0%–102.0% must be preserved. If terminal sterilization is requested, the product dossier should contain comparative stability data at 121°C for 15 min and F0 values between 8–12, according to Ph. Eur. 5.1.1 and ISO 17665-1. Process conflicts arise because the ethanol cosolvent can reduce steam penetration and require vacuum cooling, and residual water can cause API precipitation. Terminal sterilization is not applicable when the formula contains no antioxidant or when the pH is outside 5.0–7.5. In such cases, aseptic processing under ISO 13408-1 and EU GMP Annex 1 is the defined route.

In contrast to calcitriol, the 22-oxa substitution in Maxacalcitol reduces the calcemic liability at equivalent parathyroid hormone-suppressive activity in published preclinical models. Compared with alfacalcidol, Maxacalcitol does not require hepatic 25-hydroxylation for activation, which removes a metabolic activation step and reduces dependence on hepatic enzyme capacity. Compared with paricalcitol, the active substance retains the vitamin D3 nucleus rather than the 19-nor vitamin D2 scaffold, and the side-chain ether linkage alters vitamin D receptor dissociation kinetics. These differences affect not only clinical handling but also pharmaceutical development: the solubility, oxidative stability, and photostability profiles differ enough that formulation methods validated for calcitriol or alfacalcidol cannot be transferred directly to Maxacalcitol without forced degradation testing, excipient compatibility studies, and process validation. For tablet and capsule manufacture, the main operational boundary is the microgram-level drug load, which requires geometric dilution, particle size control, and strict cleaning validation. For granule and injection manufacture, the main boundary is oxygen and light exposure during processing. Published data for formulation-specific failure modes of this API in all possible vehicles is limited; therefore each formulation must be characterized using stability-indicating methods and route-specific acceptance criteria.